Understand the source comparison
Best Research Peptides for Golfer's Elbow: Protocol Comparison
BPC-157 250–500mcg Daily (subcutaneous or IM) VEGF upregulation, angiogenesis, fibroblast proliferation Moderate. Rat tendon models show 70% strength increase at 14 days Small injection volume, daily commitment, requires bacteriostatic water reconstitution Mos
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- BPC-157
- 250–500mcg
- Daily (subcutaneous or IM)
- VEGF upregulation, angiogenesis, fibroblast proliferation
- Moderate. Rat tendon models show 70% strength increase at 14 days
- Small injection volume, daily commitment, requires bacteriostatic water reconstitution
- Most researched for tendon injuries; consistent animal data but zero human RCTs
- TB-500
- 2–5mg
- Twice weekly (subcutaneous or IM)
- Actin binding, cell migration, endothelial progenitor recruitment
- Moderate. Mouse cardiac and wound healing models demonstrate vascular effects
- Large injection volume (up to 2ml per dose), less frequent dosing
- Established cell migration mechanism; expensive per cycle; human evidence remains absent
- Combined BPC-157 + TB-500
- 250–500mcg + 2–5mg
- BPC daily, TB-500 twice weekly
- Complementary angiogenic and migration pathways
- Low. No studies test combination directly
- Higher total cost, complex protocol adherence, theoretical synergy unproven
- Popular in user communities; rationale is plausible but unvalidated by research
- GHK-Cu (Copper Peptide)
- 1–3mg
- 2–3 times weekly
- Collagen synthesis, anti-inflammatory signalling, metalloproteinase modulation
- Low. Wound healing models in skin; limited tendon-specific data
- Stable in solution, less tissue-specific targeting
- Secondary option; stronger evidence for dermal wounds than deep tendon pathology